Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment

OBJECTIVE: Crizotinib is recommended as the first-line therapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Despite its initial efficacy, patients ultimately acquire resistance to crizotinib within 1 year. In such patients, the optimal sequential therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyan, Ma, Di, Yang, Guangjian, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Yang, Lu, Xu, Fei, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513749/
https://www.ncbi.nlm.nih.gov/pubmed/31156305
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.02.09

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513749/
https://www.ncbi.nlm.nih.gov/pubmed/31156305
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.02.09

Ejemplares similares